Semaglutide Reduced Risk for Major Kidney Disease Events by 24% for Patients with Type 2 Diabetes and Kidney Disease

American Diabetes Association Symposium Showcases New Potential Solution for Patients at High-Risk of Kidney Outcomes ORLANDO, Fla., June 24, 2024 /PRNewswire/ — Today, findings from the landmark FLOW trial, the first dedicated kidney outcomes trial with a GLP-1 (glucagon-like peptide-1)…